Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis

BACKGROUND: Cisplatin-based treatment has been considered the standard treatment regimen of HNSCC. Cetuximab is an emerging target therapy that has potential therapeutic benefits over cisplatin. Nevertheless, curative effects of cisplatin-based chemoradiotherapy (CRT) versus cetuximab-based bioradio...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jingwen, Zhang, Jing, Shi, Changle, Liu, Lei, Wei, Yuquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002133/
https://www.ncbi.nlm.nih.gov/pubmed/27565887
http://dx.doi.org/10.1186/s12885-016-2706-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002133/
https://www.ncbi.nlm.nih.gov/pubmed/27565887
http://dx.doi.org/10.1186/s12885-016-2706-2

Ejemplares similares